Halozyme Therapeutics (HALO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $121.84, +0.27% vs the prior close of $121.51.
- Volume 2.08M shares, 0.9x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
HALO ends flat (+0.3%) to $121.84, a 52-week high, 3 up days in a row. Closed at $121.84, +0.27% vs the prior close of $121.51. Day range $120.19–$122.44, opened at $122.24.
HALO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — HALO ends flat (+0.3%) to $121.84, a 52-week high, 3 up days in a row
- Closed at $121.84, +0.27% vs the prior close of $121.51. Day range $120.19–$122.44, opened at $122.24.
- Volume was 2.08M shares, 0.9x its 50-day average of 2.40M.
- Price is +11.9% vs its 50-day average ($108.92) and +51.1% vs its 200-day average ($80.61).
- 52-week range $61.23–$122.44; today's close sits at 99% of that range, 0.5% below the 52-week high.
- That makes 3 straight gains.
Oct 15, 2026 — HALO jumps 4.0% to $121.51, a 52-week high
- Closed at $121.51, +4.01% vs the prior close of $116.82. Day range $117.38–$122.33, opened at $118.35.
- Volume was 2.47M shares, 1.0x its 50-day average of 2.38M.
- Price is +12.3% vs its 50-day average ($108.19) and +51.2% vs its 200-day average ($80.34).
- 52-week range $61.23–$122.33; today's close sits at 99% of that range, 0.7% below the 52-week high.
Oct 14, 2026 — HALO jumps 6.6% to $116.82, a 52-week high
- Closed at $116.82, +6.57% vs the prior close of $109.62. Day range $109.42–$119.21, opened at $109.90.
- Volume was 3.77M shares, 1.6x its 50-day average of 2.33M.
- Price is +8.7% vs its 50-day average ($107.44) and +45.9% vs its 200-day average ($80.08).
- 52-week range $61.23–$119.21; today's close sits at 96% of that range, 2.0% below the 52-week high.
Oct 13, 2026 — HALO dips 1.3% to $109.62
- Closed at $109.62, -1.31% vs the prior close of $111.08. Day range $108.80–$111.92, opened at $111.92.
- Volume was 1.77M shares, 0.8x its 50-day average of 2.32M.
- Price is +2.7% vs its 50-day average ($106.76) and +37.3% vs its 200-day average ($79.84).
- 52-week range $61.23–$116.85; today's close sits at 87% of that range, 6.2% below the 52-week high.
Oct 12, 2026 — HALO rises 0.6% to $111.08
- Closed at $111.08, +0.60% vs the prior close of $110.42. Day range $109.96–$112.43, opened at $110.19.
- Volume was 1.66M shares, 0.7x its 50-day average of 2.32M.
- Price is +4.6% vs its 50-day average ($106.22) and +39.5% vs its 200-day average ($79.63).
- 52-week range $61.23–$116.85; today's close sits at 90% of that range, 4.9% below the 52-week high.
Oct 9, 2026 — HALO rises 0.5% to $110.42
- Closed at $110.42, +0.53% vs the prior close of $109.84. Day range $109.70–$112.65, opened at $109.70.
- Volume was 1.85M shares, 0.8x its 50-day average of 2.33M.
- Price is +4.5% vs its 50-day average ($105.65) and +39.0% vs its 200-day average ($79.42).
- 52-week range $61.23–$116.85; today's close sits at 88% of that range, 5.5% below the 52-week high.
Oct 8, 2026 — HALO dips 0.9% to $109.84
- Closed at $109.84, -0.86% vs the prior close of $110.79. Day range $107.41–$110.64, opened at $109.41.
- Volume was 2.49M shares, 1.1x its 50-day average of 2.31M.
- Price is +4.5% vs its 50-day average ($105.10) and +38.7% vs its 200-day average ($79.21).
- 52-week range $61.23–$116.85; today's close sits at 87% of that range, 6.0% below the 52-week high.
Oct 7, 2026 — HALO rises 1.0% to $110.79
- Closed at $110.79, +0.98% vs the prior close of $109.72. Day range $110.16–$114.00, opened at $111.62.
- Volume was 2.18M shares, 0.9x its 50-day average of 2.32M.
- Price is +5.9% vs its 50-day average ($104.57) and +40.2% vs its 200-day average ($79.00).
- 52-week range $61.23–$116.85; today's close sits at 89% of that range, 5.2% below the 52-week high.
Oct 6, 2026 — HALO rises 1.3% to $109.72
- Closed at $109.72, +1.30% vs the prior close of $108.31. Day range $107.43–$111.25, opened at $108.87.
- Volume was 1.77M shares, 0.8x its 50-day average of 2.31M.
- Price is +5.5% vs its 50-day average ($104.03) and +39.3% vs its 200-day average ($78.77).
- 52-week range $61.23–$116.85; today's close sits at 87% of that range, 6.1% below the 52-week high.
Oct 5, 2026 — HALO dips 1.4% to $108.31
- Closed at $108.31, -1.41% vs the prior close of $109.86. Day range $107.68–$109.87, opened at $109.62.
- Volume was 1.86M shares, 0.8x its 50-day average of 2.31M.
- Price is +4.7% vs its 50-day average ($103.46) and +37.9% vs its 200-day average ($78.55).
- 52-week range $61.23–$116.85; today's close sits at 85% of that range, 7.3% below the 52-week high.
Oct 2, 2026 — HALO rises 2.7% to $109.86
- Closed at $109.86, +2.73% vs the prior close of $106.94. Day range $106.65–$109.99, opened at $106.96.
- Volume was 2.60M shares, 1.1x its 50-day average of 2.29M.
- Price is +6.7% vs its 50-day average ($102.93) and +40.3% vs its 200-day average ($78.33).
- 52-week range $61.23–$116.85; today's close sits at 87% of that range, 6.0% below the 52-week high.
HALO latest news & SEC filings
Every SEC filing by or about HALO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 8, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Torley Helen converted options/RSUs into 20,000 shares at $18.41 (≈$368.20K) on Oct 6, 2026; now holds 787,780
- Torley Helen sold 2,300 shares at $107.90 (≈$248.17K) on Oct 6, 2026; now holds 785,480
- Torley Helen sold 6,000 shares at $109.33 (≈$656.00K) on Oct 6, 2026; now holds 779,480
- Torley Helen sold 9,920 shares at $109.89 (≈$1.09M) on Oct 6, 2026; now holds 769,560
- Torley Helen sold 1,780 shares at $110.81 (≈$197.25K) on Oct 6, 2026; now holds 767,780
- Torley Helen converted options/RSUs into 20,000 shares at $18.41 (≈$368.20K) on Oct 7, 2026; now holds 787,780
- …plus 9 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 8, 2026 · Form 4/A — Insider trade (amended)
Amended insider trade report (Form 4/A)
- Connaughton Bernadette received an award of 3,796 shares on May 5, 2026; now holds 42,294
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Daly James M received an award of 1,169 shares on Oct 1, 2026; now holds 1,169
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 2, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Oct 2, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Posard Matthew L. sold 730 shares at $107.17 (≈$78.23K) on Oct 1, 2026; now holds 58,109
- Posard Matthew L. sold 3,300 shares at $108.45 (≈$357.90K) on Oct 1, 2026; now holds 54,809
- Posard Matthew L. sold 1,100 shares at $109.57 (≈$120.53K) on Oct 1, 2026; now holds 53,709
- Posard Matthew L. sold 100 shares at $110.04 (≈$11.00K) on Oct 1, 2026; now holds 53,609
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 30, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 22, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.03 — Took on a new material debt or financial obligation.
- Item 3.02 — Sold unregistered shares.
Sep 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 17, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Posard Matthew L. sold 3,100 shares at $106.13 (≈$329.01K) on Sep 16, 2026; now holds 74,735
- Posard Matthew L. sold 3,000 shares at $106.83 (≈$320.48K) on Sep 16, 2026; now holds 71,735
- Posard Matthew L. sold 8,896 shares at $108.04 (≈$961.12K) on Sep 16, 2026; now holds 62,839
- Posard Matthew L. sold 4,000 shares at $108.99 (≈$435.96K) on Sep 16, 2026; now holds 58,839
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Aug 18, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $481.00M (prior year $325.72M) (+47.7% vs Jun 30, 2025)
- Net income: $229.91M (prior year $165.16M) (+39.2% vs Jun 30, 2025)
- Diluted EPS: $1.90 (prior year $1.33) (+42.9% vs Jun 30, 2025)
Aug 6, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 2, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Things to know before you trade HALO
- Last results release: Aug 6, 2026 (8-K Item 2.02). Previous ones: May 11, 2026, Feb 17, 2026, Jan 28, 2026. Based on that rhythm, the next report is likely around Nov 5, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.85% (largest 6.6%).
- Liquidity: about 2.52M shares (≈$306.54M) trade per day on average.
- 52-week position: $121.84 vs a range of $61.23–$122.44 (99% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Matthew L. Posard sold 3,000 shares on Sep 16, 2026.
- Latest filings: 8-K Sep 30, 2026; 8-K Sep 22, 2026; 8-K Sep 18, 2026.
- Share count: 113.50M shares outstanding (Jul 31, 2026), -3.0% vs a year earlier — the company has been reducing its share count.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
HALO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 122.24 | 122.44 | 120.19 | 121.84 | 2.08M |
| Oct 15, 2026 | 118.35 | 122.33 | 117.38 | 121.51 | 2.47M |
| Oct 14, 2026 | 109.90 | 119.21 | 109.42 | 116.82 | 3.77M |
| Oct 13, 2026 | 111.92 | 111.92 | 108.80 | 109.62 | 1.77M |
| Oct 12, 2026 | 110.19 | 112.43 | 109.96 | 111.08 | 1.66M |
| Oct 9, 2026 | 109.70 | 112.65 | 109.70 | 110.42 | 1.85M |
| Oct 8, 2026 | 109.41 | 110.64 | 107.41 | 109.84 | 2.49M |
| Oct 7, 2026 | 111.62 | 114.00 | 110.16 | 110.79 | 2.18M |
| Oct 6, 2026 | 108.87 | 111.25 | 107.43 | 109.72 | 1.77M |
| Oct 5, 2026 | 109.62 | 109.87 | 107.68 | 108.31 | 1.86M |
| Oct 2, 2026 | 106.96 | 109.99 | 106.65 | 109.86 | 2.60M |
| Oct 1, 2026 | 109.93 | 110.50 | 106.84 | 106.94 | 2.33M |
| Sep 30, 2026 | 111.54 | 112.45 | 110.35 | 110.40 | 3.52M |
| Sep 29, 2026 | 112.89 | 114.52 | 111.03 | 111.56 | 2.87M |
| Sep 28, 2026 | 113.34 | 113.94 | 112.10 | 112.89 | 2.24M |
| Sep 25, 2026 | 115.36 | 115.63 | 113.43 | 113.90 | 1.96M |
| Sep 24, 2026 | 112.13 | 116.09 | 111.07 | 115.22 | 3.17M |
| Sep 23, 2026 | 116.85 | 116.85 | 112.18 | 112.44 | 2.70M |
| Sep 22, 2026 | 111.50 | 115.18 | 110.95 | 115.13 | 4.15M |
| Sep 21, 2026 | 112.80 | 113.47 | 111.05 | 111.45 | 2.88M |
About Halozyme Therapeutics
Halozyme Therapeutics (HALO) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1159036.
HALO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Dannielle Appelhans | Director | Sep 2, 2026 |
| Bernadette Connaughton | Director | Aug 11, 2026 |
| Barbara Gayle Duncan | Director | May 7, 2026 |
| Jeffrey William Henderson | Director | May 7, 2026 |
| Mahesh Krishnan | Director | Jun 30, 2026 |
| James Paul Lang | Director | May 7, 2026 |
| Matthew L. Posard | Director | Sep 17, 2026 |
| Helen Torley | PRESIDENT AND CEO | Sep 11, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Cortney Caudill | SVP, CHIEF OPERATING OFFICER | Mar 10, 2026 |
| Nicole Labrosse | SVP, CHIEF FINANCIAL OFFICER | Feb 24, 2026 |
| David A Ramsay | EVP, PRESIDENT, DRUG DELIVERY | Jul 2, 2026 |
| Darren Snellgrove | SVP, Chief Financial Officer | Jul 2, 2026 |
| Mark Howard Snyder | SVP, CHIEF LEGAL OFFICER | Jun 15, 2026 |
| Helen Torley | PRESIDENT AND CEO | Sep 11, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,000 | $106.83 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 8,896 | $108.04 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,100 | $106.13 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 4,000 | $108.99 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,000 | $106.83 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 8,896 | $108.04 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,100 | $106.13 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 4,000 | $108.99 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,000 | $106.83 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 8,896 | $108.04 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,100 | $106.13 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 4,000 | $108.99 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,000 | $106.83 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 8,896 | $108.04 |
| Sep 16, 2026 | Matthew L. Posard | Sale | 3,100 | $106.13 |
HALO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $1.40B | $316.89M | 2.56 | $651.56M |
| Dec 31, 2024 | $1.02B | $444.09M | 3.43 | $479.06M |
| Dec 31, 2023 | $829.25M | $281.59M | 2.10 | $388.57M |
| Dec 31, 2022 | $660.12M | $202.13M | 1.44 | $240.11M |
| Dec 31, 2021 | $443.31M | $402.71M | 2.74 | $299.44M |
Latest balance sheet: total assets $2.58B, total liabilities $2.43B, cash $163.14M (as of Jun 30, 2026).
HALO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 6, 2026 | 8-K Item 2.02 (results) | $85.76 |
| May 11, 2026 | 8-K Item 2.02 (results) | $66.41 |
| Feb 17, 2026 | 8-K Item 2.02 (results) | $80.48 |
| Jan 28, 2026 | 8-K Item 2.02 (results) | $72.83 |
| Nov 3, 2025 | 8-K Item 2.02 (results) | $66.20 |
| Aug 5, 2025 | 8-K Item 2.02 (results) | $60.81 |
| May 6, 2025 | 8-K Item 2.02 (results) | $59.38 |
| Feb 18, 2025 | 8-K Item 2.02 (results) | $57.90 |
| Jan 8, 2025 | 8-K Item 2.02 (results) | $53.76 |
| Oct 31, 2024 | 8-K Item 2.02 (results) | $50.57 |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 7, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Biogen (BIIB)Repligen (RGEN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on HALO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.